IQM collaborates with NVIDIA on NVQLink to enable scalable quantum error correction
Collaboration underscores commitment in scaling one of the key challenges to useful quantum computing applications
IQM Quantum Computers, a global leader in superconducting quantum computers, today announced it will integrate NVIDIA’s NVQLink into its quantum computers to scale error correction, a key component for realising quantum computing applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251028095798/en/

IQM collaborates with NVIDIA on NVQLink to enable scalable quantum error correction
NVQLink is an open and interoperable platform integrated with NVIDIA CUDA-Q that connects quantum hardware to AI supercomputing. It provides low-latency and high-throughput connectivity between quantum computers and Graphics Processing Unit (GPU)-accelerated compute, enabling the real-time orchestration of computational tasks needed for running useful hybrid quantum-classical applications and quantum error correction.
While today’s quantum computers are reaching sizes that unlock algorithms in simulation, optimization, and machine learning, errors at the level of physical qubits still prevent commercial quantum advantage.
IQM’s technology roadmap focuses on quantum error correction, which reduces error rates by encoding logical qubits in clusters of physical qubits. This requires longer runtimes, and more complex compute processes on GPUs. To support this path, IQM has pioneered IQM Constellation, a unique quantum processor architecture for scalable error correction.
The partnership combines IQM’s system integration know-how and advanced processor technology, Zurich Instruments’ control systems, and the NVIDIA accelerated computing platform with scaling compute power across the timescales involved from hundreds of nanoseconds to seconds. As a result, this collaboration establishes a layered compute architecture capable of supporting workloads.
“Integrating NVQLink into our systems is a significant step towards building logical qubits and utility-scale quantum computers,” said Jan Goetz, Co-CEO and Co-founder of IQM Quantum Computers. “By combining our IQM Constellation with NVIDIA accelerated computing and Zurich Instruments’ control electronics, we can tackle one of the toughest challenges on the road to fault-tolerant quantum computing: real-time decoding and control at scale.”
Beyond error correction, NVQLink also supports hybrid quantum–classical applications by allowing seamless data flow between logical qubits and classical compute resources. This opens up new opportunities for running hybrid algorithms that require real-time feedback from large-scale compute to superconducting quantum computers.
“Quantum is reaching an inflection point, and hybrid systems will be the foundation for solving real-world problems,” said Flavio Heer, CTO at Zurich Instruments. “Collaborating closely with IQM and NVIDIA to showcase seamless end-to-end integration of classical and quantum computing, spanning both hardware and software, represents a significant advancement for hybrid classical-quantum systems, and will enable powerful demonstrations very soon.”
"Building scalable quantum accelerated supercomputing demands tighter integration between quantum processors and classical accelerated computing to tackle challenges like quantum error correction," said Tim Costa, General Manager for Quantum at NVIDIA. "QPU builders like IQM and quantum system vendors like Zurich Instruments are accelerating breakthroughs in quantum computing by using NVIDIA NVQLink as the open unified interface connecting quantum hardware to accelerated computing platforms."
About IQM Quantum Computers:
IQM is a global leader in superconducting quantum computers. IQM provides both on-premises full-stack quantum computers and a cloud platform to access its computers. IQM customers include the leading high-performance computing centers, research labs, universities, and enterprises that have full access to IQM's software and hardware. IQM has over 300 employees with headquarters in Finland and a global presence in France, Germany, Italy, Japan, Poland, Spain, Singapore, South Korea, and the United States. For more information, visit: meetiqm.com
About Zurich Instruments
Zurich Instruments is a Swiss company with a passion for phenomena that are often notoriously difficult to measure. We lead the change by providing advanced hardware, software and services for quantum computing control systems, lock-in amplifiers, impedance analyzers, and arbitrary waveform generators. As a company of scientists for scientists, we tackle challenges of research by delivering a wide product portfolio that reduces complexity of laboratory setups, unlocks new measurement strategies and complies to Swiss quality standards. Our commitment to collaborations and real-time support is reflected in seven offices worldwide, numerous research partnerships, and thousands of publications referring to Zurich Instruments. Since 2021, Zurich Instruments is a part of the Rohde & Schwarz and continues its scale up ambitions to advance science and accelerate the second quantum revolution.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251028095798/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MOPIC Unveils 32-Inch Autostereoscopic 3D Display for Endoscopic and Microscope Applications Capable of Realistic Depth and Immersive Visualization29.10.2025 09:00:00 CET | Press release
MOPIC, a leading developer of autostereoscopic 3D display technology, has unveiled its 32-inch autostereoscopic 3D display designed for 3D endoscopic and microscope imaging systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029144650/en/ MOPIC unveiled its 32-inch autostereoscopic 3D display capable of lifelike depth and spatial perception without the need for 3D glasses (Photo: MOPIC) The new product reproduces lifelike depth and spatial perception without the need for 3D glasses, setting a new benchmark for medical visualization and education. Optimized 3D Solution for Medical Training and Research The 32-inch autostereoscopic 3D display combines a display with an integrated 3D lens, an eye-tracking camera, and real-time 3D rendering software provided as an SDK. It supports standard stereo formats such as Side-by-Side, and can be directly connected to existing endoscopes or microscope systems through 3D software in
NEC to Acquire CSG, Strengthening Its Position as a Global Leader in Digital Transformation29.10.2025 08:44:00 CET | Press release
NEC Corporation (TSE: 6701) (“NEC”) and CSG Systems International, Inc. (NASDAQ: CSGS) (“CSG”) today announced they have entered into a definitive agreement under which NEC will acquire CSG for US$80.70 per share in cash, for a total enterprise value of approximately US$2.9 billion, or JPY438.5 billion, including debt. The transaction price represents a 17.38% premium over CSG’s closing price of US$68.75 on October 28, 2025, and a 23.07% premium to the volume-weighted average price (VWAP) of CSG common stock for the 30 days ending October 28, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029203825/en/ The transaction strengthens NEC's position as a leader in next-generation digital solutions and accelerates AI and cloud-driven innovation for customers across industries. It will bring together complementary software and services across digital transformation, expanding NEC's software-as-a-service (SaaS) portfolio, c
Samsung Bioepis to Commercialize BYOOVIZ® (ranibizumab) in Europe from January 202629.10.2025 08:00:00 CET | Press release
Samsung Bioepis will assume full commercial responsibility for BYOOVIZ® (ranibizumab) upon full transition of Biogen’s commercialization rights back to Samsung Bioepis effective as of January 2026BYOOVIZ, approved by the European Commission (EC) in August 2021 as the first ophthalmology biosimilar in Europe, has been commercially available in several European countries since March 2023 Samsung Bioepis Co., Ltd. announced today that the company has entered into an Asset Purchase Agreement (APA) with Biogen regarding Samsung Bioepis’ two ophthalmology assets: BYOOVIZ® (ranibizumab), a biosimilar referencing Lucentisi (ranibizumab) and OPUVIZ™ (aflibercept), a biosimilar referencing Eyleaii (aflibercept) — in Europe. Samsung Bioepis will have full responsibility for commercialization of BYOOVIZ upon the transfer of commercial rights from Biogen back to Samsung Bioepis, effective as of January 2026. “We are pleased to announce our direct commercialization initiative for BYOOVIZ in Europe.
Recover™ Secures Multi-Year Recycled Cotton Agreement with H&M29.10.2025 08:00:00 CET | Press release
Recover™ has signed a multi-year agreement with H&M to support the integration of its recycled cotton fiber, RCotton, for use in H&M’s products. Since early 2024, H&M and Recover™ have collaborated on product development, which now enables scaled commercial introduction of Recover™ mechanically recycled cotton into H&M’s collections. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029456063/en/ Recover™ has signed a multi-year agreement with H&M to support the integration of its recycled cotton fiber, RCotton, for use in H&M’s products. Recover™ combines more than 75 years of textile recycling expertise with advanced processes that deliver traceability and consistent quality at an industrial scale, operating five recycling hubs located at the heart of textile production streams in Europe, Asia and the Americas. These capabilities are essential for a global fashion player like H&M Group, where transparency, fiber performanc
Ant Group’s AQ Tops China’s AI-Native Healthcare Apps, Launching New Features for Chronic Disease and Elderly Care29.10.2025 07:28:00 CET | Press release
Ant Group’s AI healthcare service AQ is now among China’s top 7 AI-native apps and the only healthcare app on the list, based on monthly active users, according to the latest report from QuestMobile on AI applications in China. Within this group, AQ achieved the highest compound growth rate of 83.4%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251028871468/en/ Ant Group’s AI healthcare platform AQ introduces new features, including family health record sharing, to support chronic disease management and elderly care. Since its public beta as an Alipay mini-program in September 2024 and official launch as an independent app in China in June 2025, the AQ platform has served 140 million users as of September 2025. It provides more than 100 AI-powered services, including doctor recommendations, medical report analysis, and personalized health guidance. These developments come amid China’s ongoing demographic transformation. By
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom